Association of DNA methylation signatures with premature ageing and cardiovascular death in patients with end-stage kidney disease : a pilot epigenome-wide association study
Patients with end-stage kidney disease (ESKD) display features of premature aging. There is strong evidence that changes in DNA methylation (DNAm) contribute to age-related pathologies; however, little is known about their association with premature aging and cardiovascular mortality in patients with ESKD. We assayed genome-wide DNAm in a pilot case-control study of 60 hemodialysis patients with (n=30, cases) and without (n=30, controls) a fatal cardiovascular event. DNAm was profiled on the Illumina EPIC BeadChip. Four established DNAm clocks (i.e., Horvath-, Hannum-, Pheno-, and GrimAge) were used to estimate epigenetic age (DNAmAge). Epigenetic age acceleration (EAA) was derived as the residuals of regressing DNAmAge on chronological age (chroAge), and its association with cardiovascular death was examined using multivariable conditional logistic regression. An epigenome-wide association study (EWAS) was performed to identify differentially methylated CpGs associated with cardiovascular death. All clocks performed well at predicting chroAge (correlation between DNAmAges and chroAge of r=0.76-0.89), with GrimAge showing the largest deviation from chroAge (a mean of +21.3 years). There was no significant association of EAAs with cardiovascular death. In the EWAS, a CpG (cg22305782) in the FBXL19 gene had the strongest association with cardiovascular death with significantly lower DNAm in cases vs. controls (PFDR=2.0x10-6). FBXL19 is involved in cell apoptosis, inflammation, and adipogenesis. Overall, we observed more accelerated aging in patients with ESKD, although there was no significant association of EAAs with cardiovascular death. EWAS suggests a potential novel DNAm biomarker for premature cardiovascular mortality in ESKD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Epigenetics - 18(2023), 1 vom: 01. Dez., Seite 2214394 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sumida, Keiichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aging |
|---|
| Anmerkungen: |
Date Completed 22.05.2023 Date Revised 04.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/15592294.2023.2214394 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35709834X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35709834X | ||
| 003 | DE-627 | ||
| 005 | 20231226071846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15592294.2023.2214394 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM35709834X | ||
| 035 | |a (NLM)37207321 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sumida, Keiichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of DNA methylation signatures with premature ageing and cardiovascular death in patients with end-stage kidney disease |b a pilot epigenome-wide association study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.05.2023 | ||
| 500 | |a Date Revised 04.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Patients with end-stage kidney disease (ESKD) display features of premature aging. There is strong evidence that changes in DNA methylation (DNAm) contribute to age-related pathologies; however, little is known about their association with premature aging and cardiovascular mortality in patients with ESKD. We assayed genome-wide DNAm in a pilot case-control study of 60 hemodialysis patients with (n=30, cases) and without (n=30, controls) a fatal cardiovascular event. DNAm was profiled on the Illumina EPIC BeadChip. Four established DNAm clocks (i.e., Horvath-, Hannum-, Pheno-, and GrimAge) were used to estimate epigenetic age (DNAmAge). Epigenetic age acceleration (EAA) was derived as the residuals of regressing DNAmAge on chronological age (chroAge), and its association with cardiovascular death was examined using multivariable conditional logistic regression. An epigenome-wide association study (EWAS) was performed to identify differentially methylated CpGs associated with cardiovascular death. All clocks performed well at predicting chroAge (correlation between DNAmAges and chroAge of r=0.76-0.89), with GrimAge showing the largest deviation from chroAge (a mean of +21.3 years). There was no significant association of EAAs with cardiovascular death. In the EWAS, a CpG (cg22305782) in the FBXL19 gene had the strongest association with cardiovascular death with significantly lower DNAm in cases vs. controls (PFDR=2.0x10-6). FBXL19 is involved in cell apoptosis, inflammation, and adipogenesis. Overall, we observed more accelerated aging in patients with ESKD, although there was no significant association of EAAs with cardiovascular death. EWAS suggests a potential novel DNAm biomarker for premature cardiovascular mortality in ESKD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aging | |
| 650 | 4 | |a DNA methylation | |
| 650 | 4 | |a cardiovascular disease | |
| 650 | 4 | |a end-stage kidney disease | |
| 650 | 4 | |a epigenetics clock | |
| 650 | 4 | |a mortality | |
| 700 | 1 | |a Mozhui, Khyobeni |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Xiaoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Mallisetty, Yamini |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Zhongji |e verfasserin |4 aut | |
| 700 | 1 | |a Kovesdy, Csaba P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Epigenetics |d 2006 |g 18(2023), 1 vom: 01. Dez., Seite 2214394 |w (DE-627)NLM16994431X |x 1559-2308 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:1 |g day:01 |g month:12 |g pages:2214394 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15592294.2023.2214394 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 1 |b 01 |c 12 |h 2214394 | ||